SYS-CON MEDIA Authors: Liz McMillan, Sean Houghton, Glenn Rossman, Ignacio M. Llorente, Xenia von Wedel

News Feed Item

Biotech API Manufacturing Services: World Industry and Market 2014-2024

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biotech API Manufacturing Services: World Industry and Market 2014-2024

http://www.reportlinker.com/p02006105/Biotech-API-Manufacturing-Services...

Report Details

Outsourced biopharma production - new analysis announcing revenue prospects

What's the outlook for making biological active pharma ingredients (APIs) under contract? Visiongain's new report gives you predictions of those revenues from 2014. There you see financial data, also assessing trends, technologies, clients' needs, and opportunities.

That study gives you sales forecasts to 2024 at overall world market, submarket, and national level. Discover, then, what's happening for those production services - outsourcing and off-shoring for biomedicines. There you stay ahead in commercial knowledge.

So read on to explore that industry and find what its future revenues could be worth.

Sales forecasts and other information to help your research, analyses, and decisions

Our study shows you what the future holds there for pharma contract manufacturing organisations (CMOs). You see technological and commercial outlooks for producing medicinal components of biological drugs (biologics). Discover what's likely and possible.

Besides revenue forecasting to 2024, our new work shows you recent historical results, growth rates, and market shares. There you find original analysis. Explore trends and developments too. You get 68 tables, 54 charts, and four interviews with companies.

Gains through analysing those drug-making services - advantages for your work

So why miss information you need? Why struggle to find data? Instead let our analysis guide you through that outsourcing industry's present and future. Your search just got easier.

So our study could bring you quicker, easier decisions and progress. See how. Also you gain understanding to benefit your authority. Hear, then, where trends in that sector lead, exploring where the money lies.

Anyway the following sections show what you get in that new investigation.

Revenues for the world outsourced biological APIs market and submarkets

What're the secrets of that industry's progress? You find prediction of the overall world market for that biopharma production outsourcing. Our report also shows you individual revenue forecasting of three submarkets to 2024 at world level, with discussions:• Mammalian cell cultures• Microbial fermentations (culturing)• Other biotechnological systems for yielding medical products.

That work gives you feel for what stimulates and restrains that industry, also finding what its market could be worth. There you identify potentials and competition for those technologies, processes and applications.

Avoid falling behind, then, missing business or losing influence. Instead discover how you can benefit from better understanding of what's happening there from 2014.

You also find geographical revenue predictions.

National markets - what outlooks for service needs and CMOs serving biopharma?

Our work shows you individual revenue forecasts to 2024 for 14 national markets:

United States (US)

Japan

• European leaders - Germany, France, the UK, Spain, Italy (EU5), and Switzerland

• BRIC nations - Brazil, Russia, India, and China

• Other emerging producers - Singapore and South Korea.

For the pharma service providers and their customers, many opportunities exist in developed and developing countries. Rising sales of novel biological drugs and biosimilars stimulate demands for outsourced producing of biologicals. Discover what's going on.

See there how you and your organisation could gain. You find needs and outlooks. Our work explains, also discussing issues affecting that outsourcing of bioproduction.

Developments, challenges, and opportunities affecting producers of biological APIs

Our study explains forces affecting that industry and market from 2013, including these:

• Services in greatest demand for biopharma CMOs

• Development and proliferation of cell lines and expression systems

• Therapies in development (R&D) providing outsourcing opportunity for API makers

• Overcoming challenges in making vaccines and other medicines

• Revenues expected overall to 2024 for drug classes - see forecasts for monoclonal antibodies (mAbs), insulins, growth hormones, interferons, and vaccines.

And you also explore these aspects of the field:• Improving yields and efficiency in biopharmaceutical manufacture, including effects on downstream processing• Next-generation antibody development, including antibody-drug conjugates (ADCs)• Orphan drugs and personalised medicines, inc. producing APIs for clinical trials and scale-up• Single-use bioreactors for API manufacturers• Risks of overcapacity for biotechnological CMOs• Regulations affecting that drug making.

There you investigate political, economic, social, and technological questions, assessing outlooks for trade. You find what they mean for progress in that medical business.

So assess technological and commercial advances. You discover what the future holds.

Companies leading that industry and 2018 market value

What's possible for those pharma services? Our report predicts the world market for producing those therapeutic agents will reach $5.22bn in 2018, expanding to 2024.

Our analysis also shows you what organisations hold greatest potential. In particular, you explore activities of these companies:

• Boehringer Ingelheim BioXcellence

• Celltrion

• DSM Biologics

• Lonza

• Samsung BioLogics.

You also assess capabilities and activities of other firms:• Cytovance Biologics• Fujifilm Diosynth Biotechnologies• Gallus Biopharmaceuticals• AbbVie Contract Manufacturing• GSK Biopharmaceuticals• Sandoz.

You find 165 organisations mentioned. You also read interviews with four participants in the industry. Discover, then, what service providers do, say, and think, helping you stay ahead.

Ways Biotech API Manufacturing Services: World Industry and Market 2014-2024 helps

Through knowledge such as this, our new investigation benefits your work:

• Revenues there to 2024 at world level, with forecasts for three main submarkets - assess prospects for investments, marketing, and sales

• Forecasts to 2024 for 14 national markets in the Americas, Europe, and Asia -investigate developed and developing countries for commercial potentials

• Outlooks for established and rising service providers - explore competitors' results, technology, capabilities, offerings, and strategies.

Information found nowhere else, helping your searches, analyses, and decisions

That new report provides independent analysis. There you gain competitive intelligence found only in our work, finding where money lies. So investigate progress and possibilities.

See there how you could help your research, analyses, and decisions. Also find how you could save time and get more recognition for insight, benefiting your influence.

1. Executive Summary

1.1 Contract Biotech API Manufacturing: World Market Review 2013

1.2 Report Contents

1.2.1 Benefits of this Report

1.3 Methods of the Study

1.3.1 Who is this Report for?

1.3.2 Defining the Contract Biotech API Manufacturing Market

1.4 An Introduction to Biotech API Manufacturing

1.4.1 Producing Biological Drugs: An Introduction to the Manufacturing Process

1.4.1.1 Cell Line Development and Proliferation

1.4.2 There are Challenges in Manufacturing Biotech APIs

1.4.3 Outsourcing Biotech API Manufacturing

1.4.4 Future Trends in Biotech API Manufacturing

2. Contract Biotech API Manufacturing: World Market Outlook and Forecast 2014-2024

2.1 Demand for Outsourced Biotech API Manufacturing 2012-2013

2.1.1 What Services are in Greatest Demand from Biopharma CMOs?

2.2 The Outsourced Biotech API Manufacturing Market 2014-2024

2.2.1 Strong Growth for the Biological Drugs Market 2014-2024

2.2.2 Outsourced Biotech API Manufacturing Market Forecast 2014-2024

2.2.3 What Will Drive Market Growth to 2024?

2.2.4 In-House Expertise and Manufacturing Will Restrain Growth

2.2.5 Contract Biotech API Manufacturing: Submarket Shares 2014-2024

2.3 The Mammalian Cell Culture Submarket 2014-2024

2.3.1 Mammalian Cell Culture: Submarket Forecast 2014-2024

2.3.2 Antibody Drug Development Will Drive Submarket Growth to 2024

2.4 The Microbial Fermentation Submarket 2014-2024

2.4.1 Microbial Fermentation: Submarket Forecast 2014-2024

2.4.2 Submarket Drivers and Restraints 2014-2024

2.5 Chapter Summary: Strong Market Growth Forecast 2012-2024

3. Leading National Markets for Contract Biotech API Manufacturing 2014-2024

3.1 The US and Europe Dominate Contract Biopharmaceutical Manufacturing 2012-2013

3.1.1 Growth for Leading National Submarkets 2014-2024

3.1.2 How Will National Submarket Shares Change to 2024?

3.2 Contract Biotech API Manufacturing in Europe 2014-2024

3.2.1 Biotech Research Is Growing Strongly in Europe

3.2.2 The European Submarket: Revenue Forecast 2014-2024

3.2.3 Leading EU National Submarkets 2014-2024

3.2.4 Germany Is Europe's Biopharmaceutical Production Leader

3.2.5 The UK Contract Biotech API Manufacturing Submarket 2014-2024

3.2.5.1 High Demand Expected in the UK 2014-2024

3.2.6 France: Contract Biotech API Submarket Forecast 2014-2024

3.2.7 Switzerland Is a Leading Biotech R&D Destination

3.2.8 Spain: Submarket Forecast 2014-2024

3.2.9 Italy: Traditional Strength in Small Molecule APIs

3.3 The US: The Largest National Submarket for Biotech API Manufacturing

3.3.1 Expanding Clinical Capacity to Drive US Submarket Growth 2014-2024

3.4 Japan: A Relatively New Contract Biotech Manufacturing Submarket

3.4.1 Japanese Contract Biotech API Manufacturing Submarket Forecast 2014-2024

3.5 Contract Biotech API Manufacturing in Emerging Markets 2014-2024

3.5.1 Biologics Markets Are Small in Emerging Nations in 2013

3.5.2 Increased Biosimilar and Biological Drug Development 2014-2024

3.5.3 CMOs Are Investing in China

3.5.3.1 Chinese Contract Biotech API Manufacturing Submarket Forecast 2014-2024

3.5.4 Contract Biotech API Manufacturing in India 2014-2024

3.5.5 There Are Two Large Biotech CMOs in South Korea 2013

3.5.5.1 South Korea: Submarket Forecast 2014-2024

3.5.6 Increased Investment in Singapore 2014-2024

3.5.7 Governments in Brazil and Russia Are Promoting Domestic Biotech Development

3.5.7.1 Russia: Submarket Forecast 2014-2024

3.5.7.2 Brazil: Submarket Forecast 2014-2024

3.6 Chapter Summary: Outlook for Leading National Submarkets 2014-2024

4. Biotech API Manufacturing: Outlook for Leading Biological Drug Sectors 2014-2024

4.1 Antibody Therapies: The Largest Biological Drug Sector 2014-2024

4.1.1 Monoclonal Antibody Manufacturing 2013

4.1.1.1 CHO Cell Lines Dominate in 2013

4.1.1.2 Future Developments in Antibody Expression Systems

4.1.2 Outsourced Manufacturing for Antibody APIs

4.1.2.1 There Are Many Clinical Manufacturing Opportunities

4.1.3 Next-Generation Antibody Therapies Offer New Challenges for CMOs

4.2 The Outlook for Insulin Therapies 2014-2024

4.2.1 Manufacturing Trends for Insulin Analogues 2014-2024

4.2.2 Leading Insulin Analogues Are Produced In-House

4.2.3 Development Trends in the Insulin Market to 2024

4.3 Growth Hormone API Manufacturing 2014-2024

4.3.1 Outlook for the Growth Hormone Market to 2024

4.3.2 Long-Acting Therapies in Development May Provide Outsourcing Opportunities

4.4 The Interferon Therapy Market 2014-2024

4.4.1 Multiple Expression Systems Used for Leading Interferons

4.4.2 Contract Manufacturing for Commercial and Clinical Interferon Therapies

4.4.3 Is There Demand for Long-Acting Interferon Beta Therapies?

4.5 Vaccine Manufacturing: An Alternative Market Opportunity for CMOs

4.5.1 The Vaccines Market: Outlook and Forecast 2014-2024

4.5.2 Contract Manufacturing for Vaccines 2014-2024

4.5.3 Challenges in Manufacturing Vaccines

4.6 Chapter Summary: Outsourcing for Key Biological Products 2014-2024

5. Biotech API Manufacturing: Industry Trends 2014-2024

5.1 Contract Biotech API Manufacturing: Strengths and Weaknesses 2012-2013

5.1.1 Manufacturing Biological Drugs is Complex

5.2 Contract Biotech API Manufacturing: Opportunities and Threats 2014-2024

5.3 Contract Biotech API Manufacturing Market: STEP Analysis 2014-2024

5.3.1 Social Factors: Rising Demand for Biological Medicines

5.3.2 Technological Developments Will Drive More-Efficient Manufacturing

5.3.2.1 Improving Yields and Efficiency in Biopharmaceutical Manufacturing

5.3.2.2 The Impact of Higher Yields on Downstream Processing

5.3.3 Economic Pressures: Strains on Healthcare Budgets

5.3.4 Political Issues: Regulatory Developments to Affect Drug Manufacturing

5.4 Trends in Biological Drug Development 2014-2024

5.4.1 Biosimilars as an Opportunity for CMOs

5.4.2 Next-Generation Antibody Development

5.4.3 Orphan Drugs and Personalised Medicine: Smaller Batches and Greater Flexibility Will be Required

5.4.4 Manufacturing APIs for Clinical Trials and Scale-Up

5.5 Outlook for Single-Use Technologies in Biotech API Manufacturing 2014-2024

5.5.1 The Benefits of Single-Use for Biotech API Manufacturing

5.5.2 What Limitations Exist for Single-Use Technologies in 2013?

5.5.3 Single-Use in Downstream Processing

5.5.4 CMOs Are Rapidly Adopting Single-Use Systems

5.5.5 Future Directions in Single-Use Technologies for Biotech API Manufacturing

5.6 Outsourcing Trends for Biotech API Manufacturing 2014-2024

5.6.1 Biopharma Companies Continue to Invest in In-House Facilities

5.6.2 Offshoring Biotech API Manufacturing to Emerging Markets: Not a Trend for this Decade?

5.6.3 Is There a Risk of Overcapacity for the Biotech CMO Industry?

5.7 New Production Platforms for Biotech API Manufacturing to 2024

5.7.1 Plant Made Pharmaceuticals (PMPs)

5.7.2 Transgenic Systems

5.8 Chapter Summary: Industry Trends for Contract Biotech API Manufacturing to 2024

6. Leading CMOs Manufacturing Biotech APIs 2013

6.1 Four Companies Lead the Market 2013

6.1.1 Many CMOs Offer Small-Scale Biopharmaceutical Manufacturing

6.1.2 Barriers to Market Entry 2014-2024

6.1.2.1 Biologics Manufacturing Facilities Are Costly to Set Up

6.2 Boehringer Ingelheim BioXcellence

6.2.1 Investing in New Services 2012-2013

6.2.2 Expanding Manufacturing into Asia

6.3 Celltrion: Market-Leading Capacity in Asia

6.3.1 Celltrion Aims to Become a Leading Biopharmaceutical Developer

6.4 DSM Biologics

6.4.1 DSM Invests in Single-Use Technologies

6.5 Lonza

6.5.1 Lonza is a Leader in Cell Culture Scale

6.5.2 Steady Increase in Demand, 2011-2013

6.5.3 Investing in Next-Generation Biologics Production

6.6 Other Leading and Fast-Growing Market Players 2013

6.6.1 Samsung BioLogics

6.6.2 Cytovance Biologics

6.6.3 Fujifilm Diosynth Biotechnologies

6.6.3.1 Facility and Service Expansion 2012-2013

6.6.4 Gallus Biopharmaceuticals

6.6.4.1 Gallus Acquires Laureate Biopharma, Doubling Capacity in the US

6.7 Leading Biopharmaceutical Companies Operate CMO Divisions

6.7.1 AbbVie Contract Manufacturing

6.7.2 GSK Biopharmaceuticals

6.7.3 Sandoz

6.8 Chapter Summary: Leading Companies 2014-2024

7. Research Interviews

7.1 Dr Stephen Taylor, SVP and Commercial Director Fujifilm Diosynth Biotechnologies

7.1.1 Biotech API Manufacturing as an Opportunity for CMOs

7.1.2 Single-Use Technologies and Biopharmaceutical Manufacturing

7.1.3 Major Technology Trends for Biologics

7.1.4 Emerging Markets in the Biotech API Manufacturing Market

7.2 Company Insight: Boehringer Ingelheim BioXcellence

7.2.1 Recent Demand for Contract Biomanufacturing

7.2.1.1 Future Demand for Services

7.2.2 Drug Development Trends Affecting Biopharmaceutical CMOs

7.2.3 Commercial Drivers and Restraints

7.3 Dr Abhinav Shukla, Vice President, Process Development and Manufacturing, KBI Biopharma

7.3.1 KBI Biopharma

7.3.2 Single-Use Technologies in Biopharma Manufacturing

7.3.3 Demands for Biopharma Manufacturing Services

7.3.4 Outlook for the US Contract Manufacturing Market

7.4 Dr Stefan Beyer, CEO, Vibalogics

7.4.1 Vibalogics: Company Overview

7.4.2 Outsourcing Vaccine Manufacturing

7.4.3 Challenges in Vaccine Manufacturing

7.4.4 Developments in Technology and Vaccine R&D to Affect CMOs

8. Conclusions to Our Study

8.1 The Contract Biotech API Manufacturing Market 2012-2013

8.1.1 Mammalian Cell Culture Dominates Outsourced Biotech API Manufacturing in 2013

8.1.2 The US and Europe Supplied 80% of the World's Outsourced Biotech APIs in 2012

8.2 Outlook for the Biotech API Manufacturing Market 2014-2024

8.2.1 New Technology Will Stimulate Market Expansion

8.2.2 Growth in the Market 2014-2024

8.2.3 The Future of Biotech API Supply in Emerging National Markets

List of Tables

Table 1.1 Currency Exchange Rates

Table 2.1 Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2012

Table 2.2 Top Ten Bestselling Biologics: Market Sectors and Revenues ($bn), 2012

Table 2.3 Contract Biotech API Manufacturing Market: Revenues ($bn) by Sector, 2012-2013

Table 2.4 Contract Biotech API Manufacturing Market: Overall Market and Revenue Forecasts ($bn) by Sector, 2012-2024

Table 2.5 Contract Biotech API Manufacturing Market: Submarket Shares (%), 2012-2024

Table 2.6 Mammalian Cell Culture Submarket: Revenue Forecast ($bn), 2012-2024

Table 2.7 Microbial Fermentation Submarket: Revenue Forecast ($bn), 2012-2024

Table 3.1 Contract Biotech API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2012

Table 3.2 Contract Biotech API Manufacturing Market: Leading Regional and National Submarket Revenue Forecasts ($bn), 2012-2024

Table 3.3 Contract Biotech API Manufacturing Market: National Submarket Shares (%), 2012-2024

Table 3.4 Leading European Contract Biotech API Manufacturing Submarket: Leading National Submarket Revenue Forecasts ($bn), 2012-2024

Table 3.5 European Contract Biotech API Manufacturing Submarket: Revenues ($bn) and Submarket Shares (%) by Leading Country, 2012

Table 3.6 German Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.7 UK Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.8 French Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.9 Swiss Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.10 Spanish Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.11 Italian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.12 US Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.13 Japanese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.14 Contract Biotech API Manufacturing Market: Emerging National Submarket Revenue Forecasts ($bn), 2012-2024

Table 3.15 Biologics Market: Emerging Submarket Revenues ($bn) and Market Shares (%), 2012

Table 3.16 Chinese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.17 Indian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.18 South Korean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.19 Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Tuas, 2013

Table 3.20 Singaporean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.21 Russian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 3.22 Brazilian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Table 4.1 Lonza: New Biological Drug Sector Manufacturing Agreements, 2012-2013

Table 4.2 US Biologics Clinical Pipeline by Sector, 2013

Table 4.3 Monoclonal Antibody Market: Revenue Forecast ($bn), 2012-2024

Table 4.4 Monoclonal Antibody Types and Sources

Table 4.5 Blockbuster Antibody Therapies: Antibody Types and Sources

Table 4.6 Contract Manufacturers for Leading Antibody Therapies, 2013

Table 4.7 Clinical Contract Manufacturing Agreements for Antibody Therapies, 2013

Table 4.8 Next-Generation Antibody Therapy Pipeline by Drug Type, 2013

Table 4.9 Insulin Therapies Market: Revenue Forecast ($bn), 2012-2024

Table 4.10 Expression Systems for Leading Insulin Analogues

Table 4.11 Growth Hormone Market by Drug: Revenues ($bn) and Market Share (%), 2012

Table 4.12 Growth Hormones Market: Revenue Forecast ($bn), 2012-2024

Table 4.13 Selected Long-Acting Growth Hormones in Development, 2013

Table 4.14 Interferon Therapies Market: Revenue Forecast ($bn), 2012-2024

Table 4.15 Interferon API Manufacturers in the EU, 2013

Table 4.16 Vaccines Market: Revenue Forecast ($bn), 2012-2024

Table 4.17 Vaccine Contract Manufacturing Market: Revenue Forecast ($bn), 2012-2024

Table 5.1 Contract Biotech API Manufacturing Market: Strengths and Weaknesses, 2012-2013

Table 5.2 Contract Biotech API Manufacturing Market: Opportunities and Threats, 2014-2024

Table 5.3 Contract Biotech API Manufacturing Market: STEP Analysis, 2014-2024

Table 5.4 EU-Approved Biosimilars: Marketers and Manufacturers, 2013

Table 5.5 Approved Next-Generation Antibody Therapies, 2013

Table 5.6 Selected Single-Use Bioreactors Available Commercially, 2013

Table 6.1 Leading Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2013

Table 6.2 Selected Other Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2013

Table 6.3 Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2013

Table 6.4 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2012

Table 6.5 Celltrion: Revenue ($bn), 2007-2012

Table 6.6 Celltrion: Recent Biosimilar Licensing Agreements

Table 6.7 DSM Biologics: Manufacturing Capacity, 2013

Table 6.8 DSM: Pharmaceutical Contract Manufacturing: Revenue ($bn), H1 2012-2013

Table 6.9 Lonza: Biotech API Manufacturing Capacity, 2013

Table 6.10 Lonza: Revenue ($bn), 2008-2012

Table 6.11 Cytovance Biologics: Revenue ($m) and Employees, 2008 and 2013

Table 6.12 Fujifilm Diosynth Biotechnologies: Commercial Manufacturing Agreements, 2013

Table 6.13 Sandoz: Biosimilars Revenue ($m), 2011-2012

Table 8.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) and Market Shares (%) by Sector, 2012, 2015, 2018, 2021 and 2024

Table 8.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) and Market Shares (%) by Region, 2012, 2015, 2018, 2021 and 2024

List of Figures

Figure 1.1 Key Steps in the Biological Drug Manufacturing Process

Figure 1.2 Contract Biotech API Manufacturing: Major Market Trends, 2014-2024

Figure 2.1 Contract API Manufacturing: Market Shares by Sector (%), 2012

Figure 2.2 Contract Biotech API Manufacturing Market: Revenues by Sector ($bn), 2012-2013

Figure 2.3 World Biologics Market: Revenue Forecast ($bn), 2012-2024

Figure 2.4 Contract Biotech API Manufacturing Market: Revenue Forecast ($bn), 2012-2024

Figure 2.5 Contract Biotech API Manufacturing: Market Drivers, 2014-2024

Figure 2.6 Contract Biotech API Manufacturing: Market Restraints, 2014-2024

Figure 2.7 Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2018

Figure 2.8 Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2024

Figure 2.9 Mammalian Cell Culture Submarket: Revenue Forecast ($bn), 2012-2024

Figure 2.10 Mammalian Cell Culture Submarket: Drivers and Restraints, 2014-2024

Figure 2.11 Microbial Fermentation Submarket: Revenue Forecast ($bn), 2012-2024

Figure 2.12 Microbial Fermentation Submarket: Drivers and Restraints, 2014-2024

Figure 3.1 Contract Biotech API Manufacturing: Market Shares by Region (%), 2012

Figure 3.2 Contract Biotech API Manufacturing: Market Shares by Region (%), 2018

Figure 3.3 Contract Biotech API Manufacturing: Market Shares by Region (%), 2024

Figure 3.4 European Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.5 European Contract Biotech API Manufacturing Submarket: National Submarket Shares (%), 2012

Figure 3.6 German Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.7 UK Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.8 French Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.9 Swiss Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.10 Spanish Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.11 Italian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.12 US Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.13 Japanese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.14 Contract Biotech API Manufacturing Market: Emerging National Submarket Revenue Forecasts ($bn), 2012 and 2024

Figure 3.15 Biologics Market: Emerging Submarket Shares (%), 2012

Figure 3.16 Chinese Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.17 Indian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.18 South Korean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.19 Singaporean Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.20 Russian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 3.21 Brazilian Contract Biotech API Manufacturing Submarket Forecast ($bn), 2012-2024

Figure 4.1 US Biologics Clinical R&D Pipeline by Sector, 2013

Figure 4.2 Monoclonal Antibody Market: Revenue Forecast ($bn), 2012-2024

Figure 4.3 Insulin Therapies Market: Revenue Forecast ($bn), 2012-2024

Figure 4.4 Growth Hormones Market: Revenue Forecast ($bn), 2012-2024

Figure 4.5 Interferon Therapies Market: Revenue Forecast ($bn), 2012-2024

Figure 4.6 Vaccines Market: Revenue Forecast ($bn), 2012-2024

Figure 4.7 Vaccine Contract Manufacturing Market: Revenue Forecast ($bn), 2012-2024

Figure 5.1 Biosimilars Market: Revenue Forecast ($bn), 2012, 2018 and 2024

Figure 5.2 Cost-Savings for Single-Use Bioreactors

Figure 6.1 Leading Biotech API CMOs: Mammalian Cell Culture Manufacturing Scale, 2013

Figure 6.2 Leading Biotech API CMOs: Microbial Fermentation Manufacturing Scale, 2013

Figure 6.3 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2012

Figure 6.4 Celltrion: Revenue ($bn), 2007-2012

Figure 6.5 DSM: Pharmaceutical Contract Manufacturing: Revenue ($bn), H1 2012-2013

Figure 6.6 Lonza: Revenue ($bn), 2008-2012

Figure 6.7 Cytovance Biologics: Revenue ($m), 2008 and 2013

Figure 6.8 Sandoz: Biosimilars Revenue ($m), 2011-2012

Figure 8.1 Contract Biotech API Manufacturing Market: Revenue Forecast ($bn) by Sector, 2012, 2015, 2018, 2021 and 2024

Figure 8.2 Contract Biotech API Manufacturing Market: Revenue Forecast ($bn) by Region, 2012, 2015, 2018, 2021 and 2024

Companies Listed

3P Biopharmaceuticals

A5 Laboratories

AbbVie

AbbVie Contract Manufacturing (part of AbbVie)

A-Bio Pharma

Actavis

Adocia

Alexion Pharmaceuticals

Althea Technologies

Altus Pharmaceuticals

American Diabetes Association

Amgen

Apexigen

Association of the British Pharmaceutical Industry (ABPI)

AstraZeneca

Athera Biotechnologies

AutekBio

Avalanche Biotechnologies

Bachem

BaroFold

Baxter International

Bayer

Biocad

Bioceuticals Arzneimittel (part of Stada)

Biocon

Biogen Idec

Bionomics

Bioprocessing Technology Institute (BTI)

Biosidus

Boehringer Ingelheim

Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)

Bristol-Myers Squibb

Catalent Pharma Solutions

Celladon

Celltrion

Centocor Ortho Biotech (now Janssen Biotech, part of J&J)

CinnaGen

CMC Biologics

Cook Pharmica

Cornerstone Therapeutics

Critical Pharmaceuticals

Crucell (part of J&J)

CT Arzneimittel (part of Teva)

Cytogen (part of EUSA Pharma)

Cytovance Biologics

Dendreon

DSM Biologics (part of Royal DSM)

Dyax

Eclipse Therapeutics (part of Bionomics)

Eden Biodesign (part of Actavis)

Egis Pharmaceuticals

Eli Lilly

Elona Biotechnologies (part of Zimmerman Biotechnologies)

EMA Committee for Medicinal Products for Human Use (CHMP) [EU]

Emcure Pharmaceuticals

European Medicines Agency (EMA)

EUSA Pharma (part of Jazz Pharmaceuticals)

Food and Drug Administration (FDA) [US]

Fountain Biopharma

Fresenius

Fujifilm

Fujifilm Diosynth Biotechnologies

Gallus Biopharmaceuticals

GE Healthcare

Genentech (part of Roche)

Genmab

Genzyme (part of Sanofi)

GlyTech

GSK

GSK Biopharmaceuticals (part of GSK)

GTC Biotherapeutics

Hexal Arzneimittel (part of Novartis)

Hikma Pharmaceuticals

Hospira

Hospira One2One (part of Hospira)

Human Genome Sciences (part of GSK)

Hyclone (part of Thermo Fisher Scientific)

iBio

IHI Corporation

immatics

Immune Pharmaceuticals

Inno Biologics

Intellect Neurosciences

J&J

KBI Biopharma

Kemwell Biopharma

kSep Systems (part of KBI Biopharma)

Kyowa Hakko Kirin

Laureate Biopharma (part of Gallus Biopharmaceuticals0

Lek Pharmaceuticals (Sandoz)

LG Life Sciences

Lonza

Medical Research Council (MRC) [UK]

Medice

MedImmune (part of AstraZeneca)

Merck & Co.

Merck Serono

Merckle (part of Teva)

Ministry of Health [Brazil]

Ministry of Health, Labor and Welfare (MHLW) [Japan]

Mitsubishi Tanabe Pharma

Momenta Pharmaceuticals

Mylan

National Institutes of Health Center for Regenerative Medicine (NIH CRM) [US]

Nippon Kayaku

Norbitec

Novartis

Novo Nordisk

Nuron Biotech

OncoMed Pharmaceuticals

Open Monoclonal Technology (OMT)

PanGen Biotech

Pfizer

Pfizer CentreSource (part of Pfizer)

Pharming

Pharmstandard

Pharmaceutical Research and Manufacturers of America (PhRMA)

PHW Group

Pierre Guerin

Piramal Healthcare

PlantForm

PolyTherics

ProBioGen

Prolor Biotech

Protalix BioTherapeutics

Purdue Pharma

Quintiles

ratiopharm (part of Teva)

Recepta Biopharma

Reliance Life Sciences

Rentschler Biotechnologie

Ridgemont Equity Partners

Roche

Royal DSM

SAFC (part of Sigma-Aldrich)

Samsung

Samsung Bioepis

Samsung BioLogics

Sandoz (part of Novartis)

Sanofi

Sartorius Stedim Biotech

Schering-Plough (part of Merck & Co.)

Seattle Genetics

ShanghaiTech University

SICOR Biotech (part of Teva)

Stada Arzneimittel

SynCo Bio Partners

Synpromics

Synthon

TaiMed Biologics

Technology Strategy Board (TSB) [UK]

Teva Pharmaceutical Industries

Therapure Biopharma

Thermo Fisher Scientific

ThromboGenics

Toyobo Biologics

Tufts Center for the Study of Drug Development (CSDD)

UCB

UMN Pharma

Unigen (part of UMN Pharma)

University of Arkansas

Versartis

Vibalogics (part of PHW Group)

Vida Pharma

Wacker Biotech

Wave Biotech (part of GE Healthcare)

World Health Organization (WHO)

WuXi PharmaTech

Xcellerex

Zhangjiang Biotech and Pharmaceutical Base Development (ZJ Base)

Zimmerman Biotechnologies

To order this report: Biotech API Manufacturing Services: World Industry and Market 2014-2024 http://www.reportlinker.com/p02006105/Biotech-API-Manufacturing-Services-World-Industry-and-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The BPM world is going through some evolution or changes where traditional business process management solutions really have nowhere to go in terms of development of the road map. In this demo at 15th Cloud Expo, Kyle Hansen, Director of Professional Services at AgilePoint, shows AgilePoint’s unique approach to dealing with this market circumstance by developing a rapid application composition or development framework.
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is the global leader in high-end, web-based business applications. We develop, market, and support the SmartClient & Smart GWT HTML5/Ajax platform, combining the productivity and performance of traditional desktop software ...

ARMONK, N.Y., Nov. 20, 2014 /PRNewswire/ --  IBM (NYSE: IBM) today announced that it is bringing a greater level of control, security and flexibility to cloud-based application development and delivery with a single-tenant version of Bluemix, IBM's

"BSQUARE is in the business of selling software solutions for smart connected devices. It's obvious that IoT has moved from being a technology to being a fundamental part of business, and in the last 18 months people have said let's figure out how to do it and let's put some focus on it, " explained Dave Wagstaff, VP & Chief Architect, at BSQUARE Corporation, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud strategy and programs. In this Power Panel at 15th Cloud Expo (http://www.CloudComputingExpo.com...
"Our premise is Docker is not enough. That's not a bad thing - we actually love Docker. At ActiveState all our products are based on open source technology and Docker is an up-and-coming piece of open source technology," explained Bart Copeland, President & CEO of ActiveState Software, in this SYS-CON.tv interview at DevOps Summit at Cloud Expo®, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The Internet of Things is not new. Historically, smart businesses have used its basic concept of leveraging data to drive better decision making and have capitalized on those insights to realize additional revenue opportunities. So, what has changed to make the Internet of Things one of the hottest topics in tech? In his session at @ThingsExpo, Chris Gray, Director, Embedded and Internet of Things, discussed the underlying factors that are driving the economics of intelligent systems. Discover ...
SYS-CON Events announced today that Windstream, a leading provider of advanced network and cloud communications, has been named “Silver Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. Windstream (Nasdaq: WIN), a FORTUNE 500 and S&P 500 company, is a leading provider of advanced network communications, including cloud computing and managed services, to businesses nationwide. The company also offers broadband, p...
SYS-CON Media announced today that Aruna Ravichandran, VP of Marketing, Application Performance Management and DevOps at CA Technologies, has joined DevOps Journal’s authors. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done. Aruna's inaugural article "Four Essential Cultural Hacks for DevOps Newbies" discusses how to demonstrate the...
The move in recent years to cloud computing services and architectures has added significant pace to the application development and deployment environment. When enterprise IT can spin up large computing instances in just minutes, developers can also design and deploy in small time frames that were unimaginable a few years ago. The consequent move toward lean, agile, and fast development leads to the need for the development and operations sides to work very closely together. Thus, DevOps become...
Verizon Enterprise Solutions is simplifying the cloud-purchasing experience for its clients, with the launch of Verizon Cloud Marketplace, a key foundational component of the company's robust ecosystem of enterprise-class technologies. The online storefront will initially feature pre-built cloud-based services from AppDynamics, Hitachi Data Systems, Juniper Networks, PfSense and Tervela. Available globally to enterprises using Verizon Cloud, Verizon Cloud Marketplace provides a one-stop shop fo...
AppZero has announced that its award-winning application migration software is now fully qualified within the Microsoft Azure Certified program. AppZero has undergone extensive technical evaluation with Microsoft Corp., earning its designation as Microsoft Azure Certified. As a result of AppZero's work with Microsoft, customers are able to easily find, purchase and deploy AppZero from the Azure Marketplace. With just a few clicks, users have an Azure-based solution for moving applications to the...
“In the past year we've seen a lot of stabilization of WebRTC. You can now use it in production with a far greater degree of certainty. A lot of the real developments in the past year have been in things like the data channel, which will enable a whole new type of application," explained Peter Dunkley, Technical Director at Acision, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that IDenticard will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. IDenticard™ is the security division of Brady Corp (NYSE: BRC), a $1.5 billion manufacturer of identification products. We have small-company values with the strength and stability of a major corporation. IDenticard offers local sales, support and service to our customers across the United States and Canada...
SYS-CON Events announced today that AIC, a leading provider of OEM/ODM server and storage solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. AIC is a leading provider of both standard OTS, off-the-shelf, and OEM/ODM server and storage solutions. With expert in-house design capabilities, validation, manufacturing and production, AIC's broad selection of products are highly flexible and are conf...